10/8
11:36 am
spry
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $30.00 price target on the stock.
Low
Report
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $30.00 price target on the stock.
10/8
10:48 am
spry
Rating for SPRY
Low
Report
Rating for SPRY
9/20
09:48 am
spry
Rating for SPRY
Low
Report
Rating for SPRY
9/16
01:06 pm
spry
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $30.00 price target on the stock.
Low
Report
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $30.00 price target on the stock.
9/16
01:01 pm
spry
Rating for SPRY
Low
Report
Rating for SPRY
9/9
01:03 pm
spry
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $30.00 price target on the stock.
Low
Report
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $30.00 price target on the stock.
9/9
12:13 pm
spry
Rating for SPRY
Low
Report
Rating for SPRY
9/6
07:00 am
spry
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) was upgraded by analysts at William Blair to a "strong-buy" rating.
Medium
Report
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) was upgraded by analysts at William Blair to a "strong-buy" rating.
9/6
07:00 am
spry
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) was upgraded by analysts at William Blair to a "strong-buy" rating.
Medium
Report
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) was upgraded by analysts at William Blair to a "strong-buy" rating.